Analysts who follow Millendo Therapeutics Inc (MLND) on average expect it to increase 167.86% over the next twelve months. Those same analysts give the stock an average rating of Strong Buy.
That average rating earns Millendo Therapeutics Inc an Analyst Ranking of 60, which means it ranks higher than 60 of stocks, based on data compiled by InvestorsObserver.
Why are Analyst Ratings Important?
Though analyst projections should not be your only resource when determining your position on a stock, it can be a very useful tool. Analysts follow sectors/industries in-depth and tend to know how local and global conditions tend to affect demand and prices. Many analysts even participate in conference calls where they can get information to better make sense of the numbers.
InvestorsObserver averages the ratings provided by analysts and then ranks their score as a percent against the market. This allows you to compare stocks in a more comprehensive fashion than with the typical buy/sell/hold ranking.
What's Happening With Millendo Therapeutics Inc Stock Today?
Millendo Therapeutics Inc (MLND) stock is down -18.45% while the S&P 500 is up 0.47% as of 1:30 PM on Tuesday, Jan 5. MLND has fallen -$0.38 from the previous closing price of $2.06 on volume of 3,015,654 shares. Over the past year the S&P 500 is higher by 14.53% while MLND has fallen -76.44%. MLND lost -$2.41 per share the over the last 12 months.